​

Monte Rosa Therapeutics (GLUE) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Monte Rosa Therapeutics Revenue Highlights

Latest Revenue (Y)

$123.67M

Latest Revenue (Q)

$8.97M

Monte Rosa Therapeutics Revenue by Period

Monte Rosa Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$123.67M63.54%
2024-12-31$75.62M100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Monte Rosa Therapeutics generated $123.67M in revenue during NA 2025, up 63.54% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Monte Rosa Therapeutics Revenue by Quarter

DateRevenueChange
2026-06-30$8.97M113.02%
2026-03-31$4.21M51.38%
2025-12-31$2.78M-78.22%
2025-09-30$12.77M-44.95%
2025-06-30$23.19M-72.69%
2025-03-31$84.93M40.04%
2024-12-31$60.65M558.06%
2024-09-30$9.22M96.29%
2024-06-30$4.70M341.26%
2024-03-31$1.06M100.00%
2023-12-31-100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Monte Rosa Therapeutics generated $8.97M in revenue during Q2 2026, up 113.02% compared to the previous quarter, and up 10.56% compared to the same period a year ago.

Monte Rosa Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$262.60M$249.70M
GERNGeron$183.88M$57.48M
DNAGinkgo Bioworks$170.16M$20.16M
DAWNDay One Biopharmaceuticals$158.18M$39.80M
VALNValneva SE$153.70M$32.75M
GLUEMonte Rosa Therapeutics$123.67M$8.97M
TBPHTheravance Biopharma$107.46M$20.73M
VIRVir Bio$68.56M$238.95M
MGTXMeiraGTx$33.28M$321.43M
REPLReplimune Group--
AVBPArriVent BioPharma--

GLUE Revenue FAQ

What is Monte Rosa Therapeutics’s yearly revenue?

Monte Rosa Therapeutics's yearly revenue for 2025 was $123.67M, representing an increase of 63.54% compared to 2024. The company's yearly revenue for 2024 was $75.62M, representing an increase of 100.00% compared to 2023. GLUE's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022.

What is Monte Rosa Therapeutics’s quarterly revenue?

Monte Rosa Therapeutics's quarterly revenue for Q2 2026 was $8.97M, a 113.02% increase from the previous quarter (Q1 2026), and a -61.33% decrease year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $4.21M, a 51.38% increase from the previous quarter (Q4 2025), and a -95.04% decrease year-over-year (Q1 2025). GLUE's quarterly revenue for Q4 2025 was $2.78M, a -78.22% decrease from the previous quarter (Q3 2025), and a -95.41% decrease year-over-year (Q4 2024).

What is Monte Rosa Therapeutics’s revenue growth rate?

Monte Rosa Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 0%, and for the last 5 years (2021-2025) was 0%.